Communiqués MBX Biosciences, Inc.

Actions

MBX

US55287L1017

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 20:38:59 12/05/2026			Varia. 5j.	Varia. 1 janv.
36,94 ^USD	-7,82%		+25,34%	+17,63%

11/05	Mbx Biosciences : un dirigeant cède pour 2 685 515 dollars d'actions, selon un document de la SEC	MT
11/05	Transcript : MBX Biosciences, Inc. - Special Call

Communiqués

11/05	MBX Biosciences : May 2026 Obesity Day Presentation – Final	PU
11/05	MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing	AQ
07/05	MBX Biosciences : Company Overview - May 2026	PU
07/05	MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights	AQ
07/05	MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award	AQ
23/04	MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio	AQ
03/04	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
12/03	MBX Biosciences : Company Overview - March 2026	PU
12/03	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights	AQ
10/03	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer	AQ
09/03	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism	AQ
23/02	MBX Biosciences to Participate in Upcoming March Investor Conferences	AQ
11/02	MBX Biosciences to Participate in Upcoming Investor Conferences	AQ
22/01	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair	AQ
14/01	MBX Biosciences : Company Overview - January 2025	PU
11/01	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference	AQ
15/12	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13	AQ
18/11	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference	AQ
06/11	MBX Biosciences : Company Overview - November 2025	PU
06/11	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
20/10/25	MBX Biosciences to Participate in November Investor Conferences	AQ
29/09/25	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum	AQ
25/09/25	MBX Biosciences Announces Pricing of Upsized Public Offering	AQ
22/09/25	MBX Biosciences Announces Proposed Public Offering	AQ
22/09/25	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension	AQ